News & Views

  • Merck Announces €59 Million Antibody-Drug Conjugate Manufacturing Expansion
    Merck is expanding its HPAPI and ADC manufacturing capabilities and capacity at its Madison facility.

Merck Announces €59 Million Antibody-Drug Conjugate Manufacturing Expansion

Sep 11 2020 Read 1126 Times

Merck has announced a €59 million expansion of its HPAPI and ADC manufacturing capabilities and capacity at its facility near Madison, Wisconsin, USA. This investment will allow large-scale manufacturing of increasingly potent compounds for therapies that have the potential to treat cancer. Completion is expected by mid-2022 and should add approximately 50 full-time jobs starting in 2021.

“ADCs have posted incredible growth over the last decade, and regulatory agencies’ approval in recent years demonstrate their promise as a targeted therapy,” said Andrew Bulpin, head of Process Solutions, Life Science, at Merck. “With more than 35 years of experience in this space, we have been a frontrunner in the development and manufacturing of biologics, conjugation processes and small molecules. This investment underscores our commitment to working with innovators to bring new treatments to patients quickly and more efficiently.” 

Merck’s new 6,500 m2 commercial building will be one of the largest dedicated HPAPI manufacturing facilities specifically designed to handle single-digit nanogram occupational exposure limit materials. The project is an addition to the company’s Madison campus, which was the first commercial ADC facility in North America designed to handle highly active materials. The new building will join Merck’s established campus in St Louis, Missouri, USA, which specialises in ADC bio-conjugation, active pharmaceutical ingredients, excipient and adjuvants manufacturing. 

More information online

Reader comments

Do you like or dislike what you have read? Why not post a comment to tell others / the manufacturer and our Editor what you think. To leave comments please complete the form below. Providing the content is approved, your comment will be on screen in less than 24 hours. Leaving comments on product information and articles can assist with future editorial and article content. Post questions, thoughts or simply whether you like the content.

Post a Comment





Digital Edition

Lab Asia December 2020

December 2020

In This Edition Articles - The Movement Towards More Comprehensive Testing of Mycotoxins in Cannabis - Addressing proper HACCP implementation - Micropatterning: The art of micro-controlling...

View all digital editions

Events

CISILE 2020 - NEW DATES

Dec 08 2020 Beijing, China

PHAR-EAST - NEW DATES

Dec 08 2020 VIrtual event

Nano Tech 2021 - NEW DATES

Dec 09 2020 Tokyo, Japan

Medical Fair Asia 2020 - NEW DATES

Dec 09 2020 Virtual event

View all events